WOBURN, Mass., Jan. 4, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc., a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders, today announced that the company will present at the 31st Annual J.P. Morgan Healthcare Conference.
Michael Clayman, M.D., Flexion's chief executive officer, is scheduled to present a corporate overview at 11:30 a.m. PST on Wednesday, January 9, 2013 in the Elizabethan C/D Ballroom of the Westin St. Francis Hotel. The conference will be held from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco, CA.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety, we are merging novel pharmacology with local, sustained delivery of drug to the site of disease an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid, is currently being evaluated in a Phase 2b dose-ranging study with data expected in the middle of 2013. FX007, an intra-articular sustained release TrkA inhibitor, is being developed to safely address the intractable pain associated with end-stage osteoarthritis.
For more information please visit www.flexiontherapeutics.com.
Lisa Davidson, MBA
Vice President, Finance and Administration
Tony Russo, Ph.D.
Matt Middleman, M.D.
SOURCE Flexion Therapeutics, Inc.